Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Low-risk neuroblastoma (INRG very low and low risk, including stage MS), drawn from the whole corpus: 1 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Distinguishing tumours that will regress from those that will grow without biopsy.
When surgery to the kidney or spinal canal is riskier than watching.
Identifying the few stage MS infants with MYCN amplification or 11q loss who behave as high risk.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 5 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.